Mr. Boothe is a dynamic pharmaceutical leader with extensive accomplishments in the specialty, generic, and over-the-counter pharmaceutical markets. Prior to joining Edenbridge, now Dexcel Pharma USA, Doug was President and CEO of Akorn Pharmaceuticals. Doug was previously the President, Generic Business for Impax Laboratories up to the company’s acquisition by Amneal Pharmaceuticals. Prior pharmaceutical leadership roles include Executive Vice President and Generic Manager of Perrigo Company’s Specialty and Generic Pharmaceutical business, CEO of Actavis Inc., Vice President/General Manager at Alpharma, and Vice President, Emerging Technologies at Pharmacia Inc. Doug holds an MBA from the Wharton School of Business and a BSE in Mechanical and Aerospace Engineering from Princeton University. Doug has served on the Board of Directors for Euclid Systems (a specialty contact lens manufacturer) and on the Executive Board for the Generic Pharmaceutical Association (GPhA n/k/a Association for Accessible Medicines).

As Dexcel Pharma USA COO, Mr. Ben-Anat oversees the company’s operational resources including external manufacturing and supply, Quality, R&D, and Regulatory Affairs. Prior to joining Edenbridge, now Dexcel Pharma USA, Itamar was the AVP of Strategic Operations and Project Management for Lannett Company, where he was responsible for the end-to-end delivery of the company’s new product development and new product launch programs, as well as for Portfolio Governance and Alliance Management. Previously, Itamar spent 15 years with Teva Pharmaceuticals where he held positions of increasing responsibility in the areas of Specialty R&D, Global Operations, and Commercial. Itamar holds a B.Sc. in Industrial Engineering and Management and a B.Sc. in Civil Engineering both from the Technion – Israel institute of Technology, as well as an MBA from Bar-Ilan University, Israel.

Mr. White is responsible for the development and execution of Dexcel Pharma USA’s generic sales & marketing strategy and leading all trade relations, product launches, sales infrastructure, customer service, and sales logistics related to Edenbridge’s generic product portfolio. Prior to joining Edenbridge, now Dexcel Pharma USA, Mr. White held various sales & marketing roles at Nostrum Laboratories, Actavis, Rising Pharmaceuticals, and PACK Pharmaceuticals. Mr. White holds a B.A. in Political Science from Purdue University.

Mr. Nowack is responsible for all internal quality systems, oversight of external quality activities and DSCSA compliance for Dexcel Pharma USA. Mr. Nowack has over 21 years of experience in the pharmaceutical industry with 15 years in quality assurance. Prior to joining Edenbridge, now Dexcel Pharma USA, Mr. Nowack was most recently the site quality head for Aprecia Pharmaceuticals. Mr. Nowack holds a B.S. degree in biotechnology from Rutgers University.

Ms. Jomisko is responsible for marketing activities, including generic product pricing, launch strategies and planning, while reinforcing trade relations by overseeing sales operations and customer service. Ms. Jomisko is an accomplished leader that has held commercial operations and marketing positions throughout her career in multinational publicly traded companies as well as smaller, privately held life science companies both with pharmaceutical manufacturers and wholesalers.  Prior to joining Edenbridge, now Dexcel Pharma USA, she held leadership positions at Dr. Reddy’s Laboratories, North America, as Director of Pricing and Director of Commercial Contracts. Prior to that, Ms. Jomisko has held diverse roles of increasing responsibility at Hi-Tech Pharmaceuticals, Cardinal Heath and Bellco Drug. Ms. Jomisko holds a B.S. degree in Biology from Roanoke College.